Protagonist Therapeutics, Inc financial data

Symbol
PTGX on Nasdaq
Industry
Pharmaceutical Preparations
Location
7707 Gateway Blvd., Suite 140, Newark, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Protagonist Inc (to 9/28/2006)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.44K % +57.7%
Debt-to-equity 11 % -11.9%
Return On Equity 39.1 %
Return On Assets 35.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58.9M shares +2.39%
Common Stock, Shares, Outstanding 58.8M shares +2.21%
Entity Public Float 1.6B USD +322%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 61.3M shares +7.98%
Weighted Average Number of Shares Outstanding, Diluted 61.3M shares +7.98%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 127M USD +9.43%
General and Administrative Expense 40.1M USD +28%
Operating Income (Loss) 152M USD +8.41%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -31.3M USD +18.6%
Income Tax Expense (Benefit) -676K USD
Net Income (Loss) Attributable to Parent 170M USD +20.4%
Earnings Per Share, Basic 2.87 USD/shares +26.5%
Earnings Per Share, Diluted 2.72 USD/shares +26.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 356M USD +51.1%
Marketable Securities, Current 208M USD +167%
Other Assets, Current 1.33M USD
Assets, Current 571M USD +80.1%
Property, Plant and Equipment, Net 1.78M USD +40.9%
Operating Lease, Right-of-Use Asset 10.3M USD +403%
Assets 615M USD +91.8%
Accounts Payable, Current 3.63M USD -20.6%
Accrued Liabilities, Current 15.2M USD -21.7%
Contract with Customer, Liability, Current 69K USD -92.3%
Liabilities, Current 41.6M USD +57.5%
Operating Lease, Liability, Noncurrent 11M USD
Liabilities 73.3M USD +178%
Accumulated Other Comprehensive Income (Loss), Net of Tax -249K USD -25.8%
Retained Earnings (Accumulated Deficit) -439M USD +27.9%
Stockholders' Equity Attributable to Parent 541M USD +84.1%
Liabilities and Equity 615M USD +91.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.4M USD +20.1%
Net Cash Provided by (Used in) Financing Activities 7.2M USD -72.8%
Net Cash Provided by (Used in) Investing Activities 6.07M USD -38.2%
Common Stock, Shares Authorized 180M shares +100%
Common Stock, Shares, Issued 58.8M shares +2.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.2M USD -829%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 356M USD +51%
Deferred Tax Assets, Valuation Allowance 166M USD +20.4%
Deferred Tax Assets, Gross 166M USD +20%
Operating Lease, Liability 11M USD
Depreciation 249K USD +38.3%
Payments to Acquire Property, Plant, and Equipment 242K USD +2320%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 170M USD +20.5%
Lessee, Operating Lease, Liability, to be Paid 13M USD
Property, Plant and Equipment, Gross 8.48M USD +21.4%
Operating Lease, Liability, Current 462K USD -82.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.79M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.12M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.07M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.88M USD
Deferred Tax Assets, Operating Loss Carryforwards 70.5M USD -7.44%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 28M USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.98M USD
Operating Lease, Payments 696K USD +3.26%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 236K USD -4.84%
Share-based Payment Arrangement, Expense 31.7M USD +15.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%